A recent study published in JAMA Network Open by the American Medical Association (AMA) reveals that individuals with eating disorders rated marijuana and certain psychedelics among the most effective substances for symptom relief. These self-reported evaluations surpassed those of traditional psychiatric medications in perceived efficacy.
Participants were asked to assess a wide array of psychoactive substances—including caffeine, alcohol, nicotine, prescription psychotropic drugs, classical psychedelics, ketamine, MDMA, stimulants, opioids, and others—for their impact on the symptoms of eating disorders. Among this broad spectrum, cannabis, psilocybin, and LSD emerged as the most favorably rated for alleviating eating disorder symptoms.
The authors of the study emphasized that these favorable subjective ratings of psychedelics and cannabis substantially surpassed those attributed to commonly prescribed psychiatric treatments.
The AMA study’s findings introduce a provocative dimension to the scientific conversation, particularly concerning patient-reported outcomes and the therapeutic potential of less widely endorsed substances. However, because these results rely on subjective self-reporting, rigorous clinical trials are needed to substantiate both safety and efficacy.
This investigation may catalyze a deeper exploration into unconventional treatment modalities for eating disorders, potentially influencing future clinical research. Nevertheless, established protocols remain centered on psychotherapy and evidence-supported pharmacological treatments, underscoring the importance of integrated and regulated approaches.
Dabbin-Dad Newsroom
